Affordable Access

deepdyve-link
Publisher Website

Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study.

Authors
  • Echeverria-Esnal, D1
  • Sorli, L2
  • Prim, N3
  • Conde-Estévez, D4
  • Mateu-De Antonio, J5
  • Martin-Ontiyuelo, C6
  • Horcajada, J P2
  • Grau, S7
  • 1 Service of Pharmacy, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, Spain. , (Spain)
  • 2 Service of Infectious Diseases, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, Spain. , (Spain)
  • 3 Service of Microbiology, Laboratori de Referència de Catalunya, Barcelona, Spain. , (Spain)
  • 4 Service of Pharmacy, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. , (Spain)
  • 5 Service of Pharmacy, Hospital del Mar, Barcelona, Spain. , (Spain)
  • 6 Service of Pneumology, Hospital del Mar, Barcelona, Spain. , (Spain)
  • 7 Service of Pharmacy, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: [email protected] , (Spain)
Type
Published Article
Journal
International journal of antimicrobial agents
Publication Date
Nov 01, 2019
Volume
54
Issue
5
Pages
572–578
Identifiers
DOI: 10.1016/j.ijantimicag.2019.08.018
PMID: 31476435
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The incidence of ampicillin-resistant Enterococcus faecium bacteraemia is increasing. Vancomycin remains the first-line treatment in areas with a high prevalence of glycopeptide-susceptible isolates, but data comparing its clinical outcomes with other treatments are lacking. The objective of this study was to compare the effectiveness and safety of linezolid and glycopeptides for the treatment of glycopeptide-susceptible E. faecium bloodstream infection (GSEF-BSI). This retrospective observational cohort study was conducted from January 2006 to May 2018 at the Hospital del Mar, Barcelona, Spain, and compared the clinical outcomes and safety of linezolid and glycopeptides in adult patients with GSEF-BSI. The main outcomes included clinical cure at the end of therapy, 30-day mortality, microbiological eradication and attributable length of stay (LOS). Propensity score matching was performed to reduce potential confounders among groups. In total, 105 patients with GSEF-BSI were included (linezolid, n=38; glycopeptides, n=67). After propensity score matched analysis, 56 (53.3%) patients, 28 in each cohort, entered the final analysis. No differences were observed in any of the main clinical outcomes among patients treated with linezolid or glycopeptides: clinical cure [16/28 (57.1%) vs 13/28 (46.4%), P=0.593], 30-day mortality [8/28 (28.6%) vs 12/28 (42.9%), P=0.403], microbiological eradication [22/28 (78.6%) vs 20/28 (71.4%), P=0.758] and median attributable LOS (18.0 vs 17.0 days, P=0.924). Adverse events were similar in both groups. Linezolid and glycopeptides showed similar clinical effectiveness and safety in the treatment of GSEF-BSI. Linezolid could be an alternative to glycopeptides in the treatment of GSEF-BSI. Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Report this publication

Statistics

Seen <100 times